应用血清PIVKA-II诊断肝细胞癌研究进展*

doi:10.3969/j.issn.1672-5069.2019.06.040

Abstract

Abstract: Primary liver cancer （PLC） is one of the most common malignant tumors in China. Early diagnosis of liver cancer is crucial for the outcome of patients with PLC. Protein induced by vitamin K absence or antagonist II（PIVKA-II） is a new serum tumor marker documented in recent years. It has a diagnostic value for hepatocellular carcinoma,reportedly better than the widely used serum tumor marker alpha-fetoprotein （AFP）. In this paper,we reviewed the progress of PIVKA-II in the fundamental research and clinical application.

Key words: Hepatocellular carcinoma, Tumor marker, Protein induced by vitamin K absence or antagonist II, Diagnosis

Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.

References

[1] Chen WQ,Zheng RS,Zhang SW.Liver cancer incidence and mortality in China,2009. Chin J Cancer,2013,32(4):162-169.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015. CA Cancer J Clin,2016,66(2):115-132.
[3] May M.Statistics:attacking an epidemic. Nature,2014,509(7502):S50-51.
[4] Singal AG,Marrero JA,Yopp A.Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw,2014,12(3):375-382.
[5] Bruix J,Sherman M.Management of hepatocellular carcinoma:an update. Hepatology,2011,53(3):1020-1022.
[6] EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatol,2012,56(4):908-943.
[7] Zhu R,Yang J,Xu L,et al.Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma:a Meta-analysis. Gastroenterol Res Pract,2014,2014:529314.
[8] Liebman HA,Furie BC,Tong MJ,et al.Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med,1984,310(22):1427-1431.
[9] Lok AS,Sterling RK,Everhart JE,et al.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology,2010,138(2):493-502.
[10] Inagaki Y,Tang W,Makuuchi M,et al.Clinical and molecular insights into the hepatocellular carcinoma tumor marker des-γ-carboxyprothrombin. Liver Int,2011,31(1):22-35.
[11] Fajardo-Puerta AB,Mato PM,Frampton AE,et al.Gene of the month:HGF. J Clin Pathol,2016,69(7):575-579.
[12] Suzuki M,Shiraha H,Fujikawa T,et al.Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem,2005,280(8):6409-6415.
[13] Ma M,Qu XJ,Mu GY,et al.Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin. Chemotherapy,2009,55(1):28-35.
[14] Fujikawa T,Shiraha H,Ueda N,et al.Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem,2007,282(12):8741-8748.
[15] Wang SB,Cheng YN,Cui SX,et al.Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis,2009,26(5):469-477.
[16] Fujikawa T,Shiraha H,Yamamoto K.Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med Okayama,2009,63(6):299-304.
[17] Zhang YS,Chu JH,Cui SX,et al.Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cell Physiol Biochem,2014,34(3):903-915.
[18] Dhir M,Melin AA,Douaiher J,et al.A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg,2016,263(6):1112-1125.
[19] Bruix J,Reig M,Sherman M.Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma. Gastroenterology,2016,150(4):835-853.
[20] Toyoda H,Kumada T,Tada T,et al.Tumor markers for hepatocellular carcinoma:simple and significant predictors of outcome in patients with HCC. Liver Cancer,2015,4(2):126-136.
[21] Wang CH,Wey KC,Mo LR,et al.Current trends and recent advances in diagnosis,therapy,and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev,2015,16(9):3595-3604.
[22] Weitz IC,Liebman HA.Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma:a critical review. Hepatology,1993,18(4):990-997.
[23] Nakamura S,Nouso K,Sakaguchi K,et al.Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol,2006,101(9):2038-2043.
[24] Baek YH,Lee JH,Jang JS,et al.Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology,2009,56(91-92):763-767.
[25] Ji J,Wang H,Li Y,et al.Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis b virus-related hepatocellular carcinoma in China:a large-scale,multicentre study. PLoS One,2016,11(4):e0153227.
[26] Yamamoto K,Imamura H,Matsuyama Y,et al.Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol,2009,16(10):2795-2804.
[27] Poté N,Cauchy F,Albuquerque M,et al.Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol,2015,62(4):848-854.
[28] Shirabe K,Itoh S,Yoshizumi T,et al.The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol,2007,95(3):235-240.
[29] Shimada M,Yonemura Y,Ijichi H,et al.Living donor liver transplantation for hepatocellular carcinoma:a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc,2005,37(2):1177-1179.
[30] Kim DY,Choi MS,Lee JH,et al.Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol,2006,12(43):6992-6997.
[31] Kim JM,Hyuck C,Kwon D,et al.Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg,2013,37(6):1371-1378.
[32] Lou J,Zhang L,Lyu S,et al.Biomarkers for hepatocellular carcinoma. Biomark Cancer,2017,9:1-9.
[33] Forner A,Reig M,Bruix J.Hepatocellular carcinoma,Lancet,2018. 391:1301-1314.
[34] Juárez-Hernández E,Motola-Kuba D,Chávez-Tapia NC,et al.Biomarkers in hepatocellular carcinoma:an overview. Expert Rev Gastroenterol Hepatol,2017,11(6):549-558.
[35] Toyoda H,Kumada T,Tada T,et al.Prognostic significance of a combination of pre-and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol,2012,57(6):1251-1257.
[36] Chon YE,Choi GH,Lee MH,et al.Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer,2012,131(10):2332-2341.
[37] Lee MH,Kim SU,Kim dY,et al. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol,2012,27(2):313-322.
[38] Park SJ,Jang JY,Jeong SW,et al.Usefulness of AFP,AFP-L3,and PIVKA-II,and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore),2017,96(11):e5811.

Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[6]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[7]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[8]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[9]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[10]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[11]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[12]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[13]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[14]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[15]	Zhang Junfei, Xu Heming, Song Haiyan, et al. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome:poor diagnostic sensitivity of Paris' criteria in Chinese patients [J]. Journal of Practical Hepatology, 2019, 22(4): 537-540.